Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IvIg for Secondary Recurrent Miscarriage
NCT00722475Phase 3Completed
- Sponsor
- Rigshospitalet
- Start
- Aug 2008
- Primary completion
- May 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in recurrent miscarriage (RPL) comparing IvIg Arm with Placebo Arm (2 arms). Primary endpoint: Subsequent Livebirth Rate (ITT). Started Aug 2008; status: completed.
02
Drugs
intravenous immunoglobulin G
03
Conditions
recurrent miscarriage (RPL)
Beyond the preview
Go deeper on NCT00722475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00722475.